<SEC-DOCUMENT>0000914475-22-000004.txt : 20220106
<SEC-HEADER>0000914475-22-000004.hdr.sgml : 20220106
<ACCEPTANCE-DATETIME>20220106160806
ACCESSION NUMBER:		0000914475-22-000004
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220106
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220106
DATE AS OF CHANGE:		20220106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		22514895

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-20220106.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:86923635-6b90-406a-b154-27f9220dff0c,g:26aef486-214c-43dc-943f-6e3a42a6d2c0,d:3851033e37f34124bb3b58c7aea59477--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20220106</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N180L2ZyYWc6ZDRhNDYzOWZjMjFhNDZmZmFhZmZmZWU5MGMyYjQ5ZjUvdGFibGU6NzFhNTgyM2YwNWFlNDc5Njk2ODY4ZDdiMzcyMDgxZTIvdGFibGVyYW5nZTo3MWE1ODIzZjA1YWU0Nzk2OTY4NjhkN2IzNzIwODFlMl8wLTEtMS0xLTM5NTkx_1f6d0cd5-b30c-4065-b29c-e8cc0257e8db">false</ix:nonNumeric><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N180L2ZyYWc6ZDRhNDYzOWZjMjFhNDZmZmFhZmZmZWU5MGMyYjQ5ZjUvdGFibGU6NzFhNTgyM2YwNWFlNDc5Njk2ODY4ZDdiMzcyMDgxZTIvdGFibGVyYW5nZTo3MWE1ODIzZjA1YWU0Nzk2OTY4NjhkN2IzNzIwODFlMl8xLTEtMS0xLTM5NTkx_4e064c4b-6bb0-4f19-ba0e-66a81f3911b8">0000914475</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20220106.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-06</xbrli:startDate><xbrli:endDate>2022-01-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3851033e37f34124bb3b58c7aea59477_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTY4_aab5dbd6-63be-4f85-94df-64d1101cfbbb">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8yMjI_625ad343-10b8-4141-a12c-070d68023636">January&#160;6, 2022</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:21.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTY0_00fafab9-caa3-4905-9a37-3d47c2b9a193">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF8wLTAtMS0xLTM5NTkx_7f679213-763e-4c0f-b66d-de4e24e1b0e0">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF8wLTEtMS0xLTM5NTkx_1313e5a7-e032-4344-8cac-8305098e7180">0-22705</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF8wLTItMS0xLTM5NTkx_54d50c50-3a1e-4c77-b366-a8b134607ef7">33-0525145</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(State or Other Jurisdiction</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Commission</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:64.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(IRS Employer</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:64.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:63.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF80LTAtMS0xLTM5NTkx_042bcbe5-3894-4de4-a5e2-71df97aa24b2">12780 El Camino Real,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:62.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF81LTAtMS0xLTM5NTkx_d7c38c2b-4e4b-4001-a223-2132232a3c07">San Diego,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF81LTEtMS0xLTM5NTkx_ac15c120-b102-4739-961c-f392ffcb2c53">California</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF81LTItMS0xLTM5NTkx_33b3aef0-156f-40c2-b6b5-5aeedb0b4e16">92130</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:62.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:64.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTYw_53f07401-1212-4e53-b2f2-2eaf4b89df2d">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTY1_46a4bb90-f2a2-4111-b1f3-502da867050f">617-7600</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6YzEyZWI4NGE0N2QzNGMzNGI3NWE4M2RmNTYzNDA1Y2QvdGFibGVyYW5nZTpjMTJlYjg0YTQ3ZDM0YzM0Yjc1YTgzZGY1NjM0MDVjZF8yLTAtMS0xLTM5NTkx_c98fd3cf-b02a-4bd2-bcd6-2eb54032921a">Common Stock, $0.001 par value</ix:nonNumeric></span></div></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6YzEyZWI4NGE0N2QzNGMzNGI3NWE4M2RmNTYzNDA1Y2QvdGFibGVyYW5nZTpjMTJlYjg0YTQ3ZDM0YzM0Yjc1YTgzZGY1NjM0MDVjZF8yLTItMS0xLTM5NTkx_b76dd26f-2279-4502-98e1-c8ee034f3887">NBIX</ix:nonNumeric></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6YzEyZWI4NGE0N2QzNGMzNGI3NWE4M2RmNTYzNDA1Y2QvdGFibGVyYW5nZTpjMTJlYjg0YTQ3ZDM0YzM0Yjc1YTgzZGY1NjM0MDVjZF8yLTQtMS0xLTM5NTkx_4b31a445-0a4b-41d6-95ac-5aa6f6de05a9">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTY2_17c6e358-613c-49a4-aa09-32903b56ae49">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTYx_2275619d-18a2-4674-8666-d75692eae4e6">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTYy_d0fb02f4-48f2-4a38-9e67-7700ca70919c">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTYz_e012b1e0-adff-4317-a3c4-9134b964989a">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTY3_dfcad831-b804-4143-ba03-2b1e0982e2f6">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3851033e37f34124bb3b58c7aea59477_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;), issued a press release announcing preliminary fourth quarter 2021 and full year 2021 net product sales results. The Company&#8217;s financial statements for the fourth quarter 2021 and full year 2021 have not yet been completed and could result in changes to these preliminary net product sales results. The press release also contained certain expected future milestones related to the Company&#8217;s products and product candidates. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special Note Regarding Forward-Looking Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Current Report on Form 8-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect the Company&#8217;s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent the Company&#8217;s estimates and assumptions only as of the date of this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20220107exhibit991.htm">Press Release dated January 6, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3851033e37f34124bb3b58c7aea59477_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: January&#160;6, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Legal Officer</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nbix-20220107exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i939328b5b87846838e1888c8dfc33a67_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 <br>Net Product Sales Results and Future Program Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">s</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $301 Million and 56,400 Total Prescriptions</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine) Preliminary Full-Year 2021 Net Product Sales of Approximately <br>$1.1 Billion</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Supplemental New Drug Application to the U.S. Food and Drug Administration for Valbenazine for Chorea Associated with Huntington Disease Submission in the Second Half of 2022</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Data Readouts for NBI-827104, a Novel T-Type Calcium Channel Blocker, in Essential Tremor and in Epileptic Encephalopathy with Continuous Spike and Wave During Sleep in 2022</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SAN DIEGO, Jan. 6, 2022 - Neurocrine Biosciences, Inc. (Nasdaq&#58; NBIX) today provided an update on its business performance, including preliminary net product sales results of INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (valbenazine) for 2021, and key clinical development milestones for 2022 and 2023. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will discuss these updates as part of a webcast presentation at the 40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Annual J.P. Morgan Healthcare Conference to be held virtually on Monday, January 10 at 11&#58;15 a.m. Eastern Time, followed by a Question and Answer session at approximately 11&#58;35 a.m. Eastern Time. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Preliminary Fourth Quarter 2021 INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (valbenazine) Net Product Sales (Unaudited) Highlights</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Unaudited preliminary fourth quarter 2021 INGREZZA net sales were approximately $301 million and $296 million on an inventory adjusted basis</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Fourth quarter 2021 INGREZZA net sales and total prescriptions grew 25% and 32% respectively vs. fourth quarter of 2020</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Quarterly growth driven by record patients on therapy exiting 2021</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Commercial expansion to better meet the needs of healthcare professionals across diverse sites of care on track for completion by the end of Q1 2022</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company plans to provide full-year 2022 INGREZZA sales guidance on its Q4 and FY 2021 Earnings Call on February 11, 2022</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Our fourth quarter and full-year results highlight INGREZZA&#8217;s return to growth in a challenging environment. We exited 2021 helping more patients with tardive dyskinesia than ever before. Furthermore, we now have 13 clinical programs in mid-to-late-stage studies which will generate important data readouts over the next two years,&#8221; said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. &#8220;This year, our priorities are focused on INGREZZA and continuing to advance our broad pipeline. We are uniquely positioned to drive INGREZZA growth and reinvest in our pipeline to develop potential best-in-class medications that are focused on neurological, neuro-endocrine and psychiatric disorders for patients who deserve better treatment options.&#8221;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expected Future Milestones and Key Activities</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Program</font></td><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Indication</font></td><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Milestones &#47; Key Activities</font></td></tr><tr style="height:33pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Valbenazine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">*</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(VMAT2 Inhibitor)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chorea in Huntington Disease</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">File Supplemental New Drug Application in Second Half (2H) 2022</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjunctive Treatment of Schizophrenia</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Initiate 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Registrational Study in 2022&#59; Top-Line Registrational Data in 2023</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dyskinesia Due to Cerebral Palsy</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-Line Registrational Data in 2023</font></div></td></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-827104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">**</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Selective T-Type Ca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:1.12pt;vertical-align:baseline">V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Channel Blocker)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Essential Tremor</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-Line Phase 2 Data in Mid-2022</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Rare Pediatric Epilepsy&#58; CSWS</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-Line Phase 2 Data in 2H 2022</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NBI-1117568</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#8224;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Selective M4 Agonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Treatment of Schizophrenia</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiate Phase 2 Study in 2022</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New Chemical Entity</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neurological or Psychiatric Indication</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiate Phase 1 Study in 2022</font></td></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Crinecerfont</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(CRF1 Receptor Antagonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Congenital Adrenal Hyperplasia (Adult)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-Line Registrational Data in 2023</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Congenital Adrenal Hyperplasia (Pediatric)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Top-Line Registrational Data in 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-1065845</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#8225;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(AMPA Potentiator)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Inadequate Response to Treatment in </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Major Depressive Disorder</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Phase 2 Data in 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NBI-1065846</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#8225;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(GPR-139 Agonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anhedonia in Depression</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Phase 2 Data in 2023</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NBI-921352</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#8734;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Selective Na</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline">V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6 Channel Blocker)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Focal Onset Seizure in Adults</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Phase 2 Data in 2023</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key&#58; VMAT2 &#61; Vesicular Monoamine Transporter 2&#59; Ca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">V </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#61; Calcium Channel, Voltage-Gated&#59; CSWS &#61; Epileptic Encephalopathy with Continuous Spike and Wave During Sleep&#59; M4&#61; M4 Muscarinic Receptor&#59; CFR1 &#61; Corticotropin-Releasing Factor Type 1&#59; AMPA &#61; Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid&#59; GPR &#61; Orphan G  Protein Coupled Receptor&#59; Na</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1.6 &#61; Sodium Channel, Voltage-Gated</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurocrine Bioscience Partners&#58; * Mitsubishi Tanabe Pharma Corporation has commercialization rights in East Asia&#59; <br>** In-Licensed from Idorsia Pharmaceuticals&#59; &#8224; In-Licensed from Sosei Group Corporation&#59; &#8225; Partnered with Takeda Pharmaceutical Company Limited&#59; &#8734; In-Licensed from Xenon Pharmaceuticals</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Tardive Dyskinesia (TD)</font></div><div style="margin-bottom:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tardive dyskinesia (TD) is an involuntary movement disorder characterized by uncontrollable, abnormal and repetitive movements of the torso, extremities and&#47;or face, which can include hand or foot movements, rocking of the torso, lip smacking, grimacing, tongue protrusion, facial movements or blinking, as well as puckering and pursing of the lips. The condition is associated with taking certain mental health medicines such as antipsychotics, which are commonly prescribed to treat mental illnesses such as bipolar disorder, depression and schizophrenia. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of TD can be severe and are often persistent and irreversible. TD is estimated to affect approximately 600,000 people in the U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (valbenazine) Capsules</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INGREZZA, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is an FDA-approved product indicated for the treatment of adults with tardive dyskinesia, a condition associated with uncontrollable, abnormal and repetitive movements of the face, torso and&#47;or other body parts. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INGREZZA is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function, helping to regulate nerve signaling in adults with tardive dyskinesia. VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. INGREZZA, developed by Neurocrine Biosciences, is novel in that it selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. Additionally, INGREZZA can be taken for the treatment of tardive dyskinesia as one capsule, once-daily, together with most psychiatric medications such as antipsychotics or antidepressants.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Important Information</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Approved Use</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (valbenazine) capsules is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It is not known if INGREZZA is safe and effective in children.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IMPORTANT SAFETY INFORMATION</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Do not take INGREZZA if you&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">are allergic to valbenazine, or any of the ingredients in INGREZZA.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INGREZZA may cause serious side effects, including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Sleepiness (somnolence).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Do not drive, operate heavy machinery, or do other dangerous activities until you know how INGREZZA affects you.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Heart rhythm problems (QT prolongation).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> INGREZZA may cause a heart problem known as QT prolongation.<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Symptoms of QT prolongation may include&#58;</font></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.464%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">fast, slow, or irregular heartbeat</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">shortness of breath</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">dizziness or fainting</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you faint.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Abnormal movements (Parkinson-like). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Symptoms include&#58; shaking, body stiffness, trouble moving or walking, or keeping your balance.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Before taking INGREZZA, tell your healthcare provider about all of your medical conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">including if you&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tell your healthcare provider about all the medicines you take,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> including prescription and over-the-counter medicines, vitamins and herbal supplements.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The most common side effect of INGREZZA is sleepiness (somnolence). Other side effects <br>include</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> changes in balance (balance problems, dizziness) or an increased risk of falls, headache, feelings of restlessness, dry mouth, constipation, and blurred vision.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These are not all of the possible side effects of INGREZZA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please see accompanying INGREZZA full </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Product Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">About Neurocrine Biosciences</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie)</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to&#58; our preliminary unaudited financial information&#59; the benefits to be derived from our products and product candidates&#59; the value our products and&#47;or our product candidates may bring to patients&#59; the continued success of INGREZZA&#59; our financial and operating performance, including our future revenues, expenses, or profits&#59; our collaborative partnerships&#59; expectations regarding our ability to adapt our business to the evolving COVID-19 pandemic, mitigate its impact on our business, including our ability to continue conducting our ongoing clinical trials and other development activities, to protect the safety and well-being of our employees, to continue to support uninterrupted supply of INGREZZA, and to otherwise advance our business objectives&#59; and the timing of the initiation and&#47;or completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are&#58; risks and uncertainties associated with items that may be identified during the financial statement closing process that cause adjustments to the estimates included in this press release&#59; our future financial and operating performance&#59; risks associated with the commercialization of INGREZZA and ONGENTYS&#59; the impact of the evolving COVID-19 pandemic on our business and the business operations of our customers&#59; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting global, national, and local economic and financial disruptions&#59; risk and uncertainties related to any COVID-19 quarantine, social distancing and other requirements put in place by governments, customers, or clinical trial sites, including the impact of such requirements on the ability of patients to have in-person visits with their health care provider&#59; risks related to the </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">development of our product candidates&#59; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties&#59; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates&#59; risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, COVID-19 or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials&#59; risks that the potential benefits of the agreements with our collaboration partners may never be realized&#59; risks that our products, and&#47;or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse&#59; risks associated with potential generic entrants for our products&#59; and other risks described in our periodic reports filed with the SEC, including without limitation our quarterly report on Form 10-Q for the quarter ended September 30, 2021. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This press release refers to preliminary unaudited net sales in certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the comparable GAAP financial measures, which are included in this press release. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">###</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contact&#58; Neurocrine Biosciences, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tony Jewell (Media)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">858-617-7578<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;neurocrine.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Todd Tushla (Investors)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">858-617-7143</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;neurocrine.com</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nbix-20220106.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:86923635-6b90-406a-b154-27f9220dff0c,g:26aef486-214c-43dc-943f-6e3a42a6d2c0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20220106" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20220106">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220106_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220106_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.neurocrine.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nbix-20220106_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:86923635-6b90-406a-b154-27f9220dff0c,g:26aef486-214c-43dc-943f-6e3a42a6d2c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_d58890ee-2c45-4ca3-9638-12b017088b8a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_05faae00-6f9f-440f-8771-9173a0e497ff_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_dfacb683-1140-484a-9a09-174d35fc3be4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_526ed6e5-5c50-4acf-87db-cecdf52382b2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b0cdfc65-a8a7-4998-b057-38bb3099f620_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b817e5ee-2cb1-46b0-8d71-3d5884d439ed_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_cb6f8e3e-2e5e-4ac9-a899-44212cff1a97_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_aa3b11f4-3014-4862-8297-3a433188458f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3827a07b-c22a-4119-b155-5d2db03b1b23_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_feaf03b2-a83e-44ee-bd86-fe2cd6e2eb99_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_04b7c861-2bb7-45e3-938f-bcd3d676f096_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_dbaa61c8-4d6a-458b-8fa8-573985814eaa_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3633a48d-455a-470f-9a83-e8a94373ae87_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2fb44e90-d740-40df-9184-01be3de9c360_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6643fdeb-5409-494d-987c-b65bec5e34b1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_771c811b-1c0d-4f20-b53c-ed264d66c72d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b1261525-cfd6-4258-919f-3ddacd21386a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3746b27d-6a8a-499f-aa0d-53f1573788fc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a7d0515e-91f4-4d08-8c2f-29377082f67e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fe9716d3-ccfb-4a25-bc0b-1c5ac1c4be37_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6baed331-b7e2-4c9d-a8f4-a52c13033d5b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_06ef2cb7-d1f3-4b2b-99ae-11b8fab0b37c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nbix-20220106_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:86923635-6b90-406a-b154-27f9220dff0c,g:26aef486-214c-43dc-943f-6e3a42a6d2c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20220106.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b362d4e3-022c-42dd-b43f-599ac6f24108" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_DocumentType_b362d4e3-022c-42dd-b43f-599ac6f24108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4e9a17bf-3a03-4374-b5f8-99c94aa0edb1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_DocumentPeriodEndDate_4e9a17bf-3a03-4374-b5f8-99c94aa0edb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2f959c0f-e0ae-4c96-8fad-d29eb79a24c8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_EntityRegistrantName_2f959c0f-e0ae-4c96-8fad-d29eb79a24c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_dfd213fa-428c-48ba-8da1-43ffe0cc204b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_EntityIncorporationStateCountryCode_dfd213fa-428c-48ba-8da1-43ffe0cc204b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_05ed8509-2552-4e7e-a39b-afc4557888cd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_EntityFileNumber_05ed8509-2552-4e7e-a39b-afc4557888cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_013ba3b6-03cb-47ad-bdbb-e5c2bf87b4d8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_EntityTaxIdentificationNumber_013ba3b6-03cb-47ad-bdbb-e5c2bf87b4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c00c33f3-6f42-4b8c-8403-156bd7b9c2b8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_EntityAddressAddressLine1_c00c33f3-6f42-4b8c-8403-156bd7b9c2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b3740237-c010-4a4a-b19f-f47ab7aadf8c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_EntityAddressCityOrTown_b3740237-c010-4a4a-b19f-f47ab7aadf8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_af61525b-b17d-46b2-bd1a-8f167d68cf7b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_EntityAddressStateOrProvince_af61525b-b17d-46b2-bd1a-8f167d68cf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5cc5aa08-132b-4638-b3fd-9a00ca8121f4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_EntityAddressPostalZipCode_5cc5aa08-132b-4638-b3fd-9a00ca8121f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dc70f246-bb3f-42ad-8933-700b82a42b46" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_CityAreaCode_dc70f246-bb3f-42ad-8933-700b82a42b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a58cf348-20c8-409c-a59f-6aae9999cb66" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_LocalPhoneNumber_a58cf348-20c8-409c-a59f-6aae9999cb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_12cdb736-b249-46ab-96dc-8bb865dc5bdb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_Security12bTitle_12cdb736-b249-46ab-96dc-8bb865dc5bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_97df258b-d78c-4c11-bf2c-b0906699b0a1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_TradingSymbol_97df258b-d78c-4c11-bf2c-b0906699b0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7d79f233-f724-4560-9f93-803c1f5044a4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_SecurityExchangeName_7d79f233-f724-4560-9f93-803c1f5044a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_ead215db-2423-42b1-909f-fb13516c82b3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_WrittenCommunications_ead215db-2423-42b1-909f-fb13516c82b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_d9e8f4a1-81dc-4051-93bd-940db0e59764" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_SolicitingMaterial_d9e8f4a1-81dc-4051-93bd-940db0e59764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_2ba4e9f9-d7b0-4c68-8438-d5c520c02597" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_PreCommencementTenderOffer_2ba4e9f9-d7b0-4c68-8438-d5c520c02597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ddba1285-82ce-4860-9cab-1486a7cdbfb0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ddba1285-82ce-4860-9cab-1486a7cdbfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f3006311-b691-4fbc-b67a-29852e264526" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_EntityEmergingGrowthCompany_f3006311-b691-4fbc-b67a-29852e264526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_92bf893c-49e8-4f04-9c49-cc033cc8251c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_AmendmentFlag_92bf893c-49e8-4f04-9c49-cc033cc8251c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1d36f12d-fa7f-499d-8c3f-ad49ee802307" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49e11ff2-6fed-4938-9c7e-e77fc8ff9f52" xlink:to="loc_dei_EntityCentralIndexKey_1d36f12d-fa7f-499d-8c3f-ad49ee802307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140470136697816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  06,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>nbix-20220106_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20220106.xsd" xlink:type="simple"/>
    <context id="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-01-06</startDate>
            <endDate>2022-01-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N180L2ZyYWc6ZDRhNDYzOWZjMjFhNDZmZmFhZmZmZWU5MGMyYjQ5ZjUvdGFibGU6NzFhNTgyM2YwNWFlNDc5Njk2ODY4ZDdiMzcyMDgxZTIvdGFibGVyYW5nZTo3MWE1ODIzZjA1YWU0Nzk2OTY4NjhkN2IzNzIwODFlMl8wLTEtMS0xLTM5NTkx_1f6d0cd5-b30c-4065-b29c-e8cc0257e8db">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N180L2ZyYWc6ZDRhNDYzOWZjMjFhNDZmZmFhZmZmZWU5MGMyYjQ5ZjUvdGFibGU6NzFhNTgyM2YwNWFlNDc5Njk2ODY4ZDdiMzcyMDgxZTIvdGFibGVyYW5nZTo3MWE1ODIzZjA1YWU0Nzk2OTY4NjhkN2IzNzIwODFlMl8xLTEtMS0xLTM5NTkx_4e064c4b-6bb0-4f19-ba0e-66a81f3911b8">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTY4_aab5dbd6-63be-4f85-94df-64d1101cfbbb">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8yMjI_625ad343-10b8-4141-a12c-070d68023636">2022-01-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTY0_00fafab9-caa3-4905-9a37-3d47c2b9a193">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF8wLTAtMS0xLTM5NTkx_7f679213-763e-4c0f-b66d-de4e24e1b0e0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF8wLTEtMS0xLTM5NTkx_1313e5a7-e032-4344-8cac-8305098e7180">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF8wLTItMS0xLTM5NTkx_54d50c50-3a1e-4c77-b366-a8b134607ef7">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF80LTAtMS0xLTM5NTkx_042bcbe5-3894-4de4-a5e2-71df97aa24b2">12780 El Camino Real,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF81LTAtMS0xLTM5NTkx_d7c38c2b-4e4b-4001-a223-2132232a3c07">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF81LTEtMS0xLTM5NTkx_ac15c120-b102-4739-961c-f392ffcb2c53">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6NmMzNGU2YWEwNmJiNDM2YTlmMDYxYjllNjQ3NWFlN2QvdGFibGVyYW5nZTo2YzM0ZTZhYTA2YmI0MzZhOWYwNjFiOWU2NDc1YWU3ZF81LTItMS0xLTM5NTkx_33b3aef0-156f-40c2-b6b5-5aeedb0b4e16">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTYw_53f07401-1212-4e53-b2f2-2eaf4b89df2d">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTY1_46a4bb90-f2a2-4111-b1f3-502da867050f">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6YzEyZWI4NGE0N2QzNGMzNGI3NWE4M2RmNTYzNDA1Y2QvdGFibGVyYW5nZTpjMTJlYjg0YTQ3ZDM0YzM0Yjc1YTgzZGY1NjM0MDVjZF8yLTAtMS0xLTM5NTkx_c98fd3cf-b02a-4bd2-bcd6-2eb54032921a">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6YzEyZWI4NGE0N2QzNGMzNGI3NWE4M2RmNTYzNDA1Y2QvdGFibGVyYW5nZTpjMTJlYjg0YTQ3ZDM0YzM0Yjc1YTgzZGY1NjM0MDVjZF8yLTItMS0xLTM5NTkx_b76dd26f-2279-4502-98e1-c8ee034f3887">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGFibGU6YzEyZWI4NGE0N2QzNGMzNGI3NWE4M2RmNTYzNDA1Y2QvdGFibGVyYW5nZTpjMTJlYjg0YTQ3ZDM0YzM0Yjc1YTgzZGY1NjM0MDVjZF8yLTQtMS0xLTM5NTkx_4b31a445-0a4b-41d6-95ac-5aa6f6de05a9">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTY2_17c6e358-613c-49a4-aa09-32903b56ae49">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTYx_2275619d-18a2-4674-8666-d75692eae4e6">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTYy_d0fb02f4-48f2-4a38-9e67-7700ca70919c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTYz_e012b1e0-adff-4317-a3c4-9134b964989a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106"
      id="id3VybDovL2RvY3MudjEvZG9jOjM4NTEwMzNlMzdmMzQxMjRiYjNiNThjN2FlYTU5NDc3L3NlYzozODUxMDMzZTM3ZjM0MTI0YmIzYjU4YzdhZWE1OTQ3N18xL2ZyYWc6NmJkOTU5MjFhMDUxNDFjZWEyM2M4NjkzNTM0ZjIzZDgvdGV4dHJlZ2lvbjo2YmQ5NTkyMWEwNTE0MWNlYTIzYzg2OTM1MzRmMjNkOF8xNTY3_dfcad831-b804-4143-ba03-2b1e0982e2f6">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MUH?=Z:%C5%KL"-?*P/ZR:.Y@1\^U'0#7-TJ9MX[=9);_$4S^!5!+ P04
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  #@294!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    (  .!)E0XOTD6[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  .!)E297)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M X$F5.WY&F,P!   +Q   !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  .!)E2?H!OPL0(  .(,   -
M          "  7,,  !X;"]S='EL97,N>&UL4$L! A0#%     @  X$F5)>*
MNQS     $P(   L              ( !3P\  %]R96QS+RYR96QS4$L! A0#
M%     @  X$F5*K$(A8S 0  (@(   \              ( !.!   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    (  .!)E0D'INBK0   /@!   :
M      "  9@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   (  .!)E1ED'F2&0$  ,\#   3              "  7T2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  ,<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-20220106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nbix-20220106.htm">nbix-20220106.htm</File>
    <File>nbix-20220106.xsd</File>
    <File>nbix-20220106_lab.xml</File>
    <File>nbix-20220106_pre.xml</File>
    <File>nbix-20220107exhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20220106.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "nbix-20220106.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20220106_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20220106_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20220106.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20220106",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220106.htm",
      "contextRef": "i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.neurocrine.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220106.htm",
      "contextRef": "i96d8d90eb3b24dac8c28225f823625e7_D20220106-20220106",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000914475-22-000004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-22-000004-xbrl.zip
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M._^=-[+2E" 8TS"XCJH><) GI;SR_+D7AW%2_87(?_L^C!#[=!"$T^J_.\$
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M/DQO( ^0-XB4-+1OCN?MPWJ5-@C'\@WK%4SW:_?]9 >=8+?8B]D?4$L#!!0
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M=+D^Z@<J&@8G_Y&*+G>Z?JBB<UR?>.N,GYE7)R^V[R3KG](^>?%_4$L#!!0
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M(98G?G&6Q,%6_(75QW,[<* I#*IX-KEWZ9]'D7O]/G*O[U!8C%1:3L@.BFL
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MS H#;KU!Y3(^>"AC9H "\:<*ZVD)G^ECHJ)>2NVY$IUB2*6",V)R=FF=FG4
M>/9=CCT2PY :Y*;HA^!DU$4FU:8T,<QHJ@P[2&&=I[1EG]A7=[R1>,)IM3Z(
M<XZMA6S1J&T<9EO;(&*826'[' &32&I7HX"33 873.=%R:(B[+ECN_QU;,\=
MZE*3#2O#$!M!E\;KR%BA#9>AM<*"/+A$NS+E;+DJ\/=$AZ7V<<5U#L[[X=AF
M0DE?I4!IN ;; 0I%G-1:],AH#,#V()O1@/H":0@PH*9/\#MUE;1 [&A.O=1A
M"XZX3(X7"UPS&H &'YCY;6C777<6O(5FU:03T$#[F'@>]*G!EEW6**4>>0"Y
M"!N:&VGPK,[VD ?JPH9Z$N1/%=\%?L,NQP-B-VQ=U>T*?[*Y\6ZM5H&-P& *
MC,*L=S_>%K#4%M'/5$>N>RE_LU[*1SP&N7E_IZFE=P+,<(ZW0)@\Q#G, P2#
M/$"0E ,$S#;B ',CZ\11<9;'Z7'+(R8=4A-CVTY:VF11-"R5;9R7E-.Z.<6S
MYK7]PZ45>GA2"3_:=+'&"=D899M%83]!AK>@41-]LUI-TN]&(J*@I+MOE;ZQ
M[6<!"=0!$+;-!Z 6".JY&M?DU8O@H5J<0#Q0& ?H4D\'M,"RCHYD.Z"]D&"7
M1.R]-VXMW(GRJ@M7(4F1?8>>OY/NI17%H.9 (QO;&9 (%(Q0(%"PKC(K*=ME
MQ9)>1L2./&CC.#(:3J.(4XB%1HL \P5SN$:&UEJ>=R4#K#:BBU2R]<FDX*EP
ME/&*<9NCO4>*5)H DL9.<QWD%#1*NUT9R61D[[6!Q^N5?"= =#[;*.X .=YZ
M#=L5  !E?P0FP%PV][D/6K9X#X8;%&$?[8(HL-=6$+@+"L-1I6CTZ%0XF+HB
MFLV\,_IT<FQQ#&:M%8(5^,,77L ECIRHGB 6H^T/%%Y-44HK+W>$G&TX,[IU
M)I'.V(6/IKI*+#KG:JV\D^A91!>YC&7.+U\[S+$+,D'^6ZF'T/(7>[<47%]Q
M\PB3==Q\<9QK,@%<])[/_5I&/5IS+[4LSPM5ZT1VIFK17:^P&4K6*1@>12I!
M<9.I=)AA8UJ^O%XI?I]#C(E5!PF[B=0M**_B"B;\P?"N=8@$N36X/X 52,$0
M)?=*[6^./#N__'35;EVTV77K]*3]!^SN]-,5**JS3Q<K)"EF+_Y8$690J96P
MTF4CE5)4^+DU9I^]RQ5MS(XA &P.3N8(R(^2X*E8W3[*C$]X%VQ7F8F2#%6+
MLL?R""PGJ@$?@5A+\9X & D/Z SVG[=<;THWN2U3^#^$YM>73]P3OYA%\G3\
M*ND>OPVC!I$*T6-XO=P@E1."U-@=&"^V'>_[@@]'0+:@BL!C&!%'!LHI[(!'
M/? S4KP$(^L$R[#99(BBDS0=Z\._10=Z2^?XZZ),VU@3V,,)[(/ ^_YT?Y3T
M!^@O@RLY %K[M8U_A&!WD;NQ9(*;(10YTIM.LB4[6PE<OHF55\LQ\64(].OL
MJ )O;QE?&VW'G6P]1)(VQC.D\KOCOV_+^;W]ZO;N]D^/Z#B_W:SNUQ;KX?Y$
MP]Z3 /S =#0+EO$CFI441+7E&W>U>8*HRTU28294MZ0YBC-#XO,.>(H+9WZN
MT??]T6?Z"K-(#,DY/.<L[EI=O ?2&G'?'W&!_/K5&IB4=B&I ?B#6:V&^!J3
MK@LFP*Z*5[ "CO#B1EL;4U%&>&72^%US>$.9MKEEC-^B<4&1"7NO%5VM!58X
M^L/9NU:PL@W.4/S.D;NOK4"V0Q&%/"3*]&VQV]*2A_^5AG@K.WTL8J ;EUS?
MR,BHR OE#7A]3Y2/O.#5]9DA6[98F>ESFR%%(5F3R&X7A4F%)>#MH3D*VZ'\
M*,UN>6@?A<\WY-;V+"%V>(AWB\VGJG4RS^.2>;Z7F/R%[M3+LMJ*L\_D3CG%
M*76$;D+LVJ?L$5Y8G-F;I;J=RW0;BT/:&='EI4"#E$B(=Y<B X]YW\#N%K.B
M%^%!)=ZA!RQM;TGUU:#XR<9IM2 3T21=(0(G'?(7\A]6/UA[MQXNZ!LCTD56
M)ZI1/$"H+!6=!8&-'=)1?NT0J[3ZPO,QX4/H8NT5-I24$F#OQNL+#;*;F?SF
MDX7/TY>(,\0%Y@[8U-ER5!WET-A1VYS@*_M$,<UR/)[R]IUB7"I:K8U'AQY.
MK;*-[$/!K;G1_]J>FR U:)O)HZ6Y04!T@7 -)N7P@/M]3((1>.;<(P</*"8)
MX76KZ@-*%4^3?@4E-]@ ,;<9/4@CG3#56%LPE(;"<:M#'W.RXRFM&1D98]Q.
M.R$#@Q5!.:;C>"^13-5>ZTOR(%!4Y(1I+YE2X\%0 A*L5"B/465_@$3 6* 6
ME& T-@&(Q-/C%@,KO>XU:S4/L^3JM69SI4YZ9X/RTN9(&0&[]GU;0%(V$.BZ
MX"5J6>N(!'C%.A'L00H^B;:)%9<N_W!&SLTR0/F ,Y"ER-6[0&E3A&>GOJT^
M$<]>MTUOH70_]Y7G+A\&3TBJ>+QXRM$^"T26S(HW'$OCHZ8EE\AE"695)8$@
M0PO_#&47%#%*=<J-+,HMZ*9BF[U.N3/NF+@R=H,V#D:H\,#GQ*0WF'O\:N0%
M+D7."EIH$S\7%]BCL.JJ4*K,)33C.;P3BYV5GYM[N/FMX(&]=\XN;"!@)>"]
MF3<5EF+5$2RS*SM:R<"\L;=4A[.NZDY#4$(AEJ,(S6-" XIT#ELYA95$8+R&
M(_A5@V@"HN4!FC9S,(T%?"86MGK/IKK"3GHBR> KT4;2:4Q?N.5[>$I%UY,+
MQ)TTM+"A"H=9-BV]!>HRLI</8TTN^I"9ML'$5SHNQ4R?'$5F9!)0X'87=/.Y
M+.13A71L8O%+SU<!9U8+ YI"=4LC9\0(ML]'&=V(X"QZ\L#" \LO-]Y@2A,E
M9F=EE$3BK4[G=RD6+;U;15D(>+L%-O ^*D6^\G4"XH!89.4-HS-,O7:I]""^
M,#E8:6*]+J>,E 2OF:?,VCP]&K/Q.'H+7;?OT.W;Y/MV^<[$&QBDC-)!Q]YJ
MCY:H<1+,5<IAV@!)(S0KBB&<^ '1FR:YZ1;:2E58:Z7\+(6-Z&L;P**+Y^%+
M>#K"FL<TXN 64<$!?!%146")R6SA*V63BTATI;70.BA&,!W"U;_:0<F"L#O(
MRAE\^$,&L !3##3D82JF7LFK"HKO2V^3N=C1+ET^*\XKQD3 RRB%]9C4]]VQ
M3&9WV<=PX&*+Y/=1)@>YA-@C&78<8?9EX2G2*_:6=*RY@O$-5G#&6/EKR+6'
ME2),BAE*7 SHC5T%=5_&[AE!MZ^[M&TM>J@CW$R\(T-,9,<2KH#'"7W90;&*
M^\'\4=BHR&3JT:??SXZ]^C[, >PVP/QU+"OM86H*8DF"U$,7+QH;9G)WI3DS
M$%(T"J"?/:*BGJ+BS4SS)!B3MFAVR2Y6F=M"ASS=I4*8PHH$6 8N'3,Y82I\
M#VM+O8YPA:0XBQC$H1H)]UJ^%OB,WC9Z"6F4*QY",_C@HS*6K>!/7 ;.K42O
M)AB2(S@&2-7YT^:1.HS06YBJCQS1*Q+JJ!6Y"Q%DQ(FZ)!2)J_H@?#NH5+(:
M#H6I0/?!QDVJC,C'&9/^&=U460M\]EZ6&HSU!UF%21H&66J(GZ2 %EM_:JRI
M!<X4*$R.)@26*5@NM1,6%499SO%\606RQ4J-.;)IJL9(HKJV2R2.A>GPV$-V
M)3P1V!8;-&?.B/EL $IE;'Q&$0>[3&?:8O!G:IQIE3&"*WG,I:';SZ1,+C&_
MY>0%9(!]Q^UYLI39FA03_0W*D10<]M/%^Y.+]A_7A83*^+%[#QM/<FQ.GP4!
MVR6C ,F(!X #MJ,V8PN_%UG$E$"[UA0&[.1[P5^F5V8+@9#*<.6]4'60[B/7
MO]A2?4A]F/#67Y6]4@ <C$6R&V'IQ4IG++30693CFJ_DKY1K+&C!_%?:"@V9
MX.C.-K5,I\5?J=2.AN.4BK+C$/P3K$GJH1,2N3KZ''(DS<=%' /C4HQ)S'$\
M4M'-V%3*,E0F5.&9O(P<+0A.N>L>UO/"DV2\FAP3,@NJLK&H:AFC);#@-.OC
MHY4_/IIM699U@N/@>?;2;!E$$3<!9DA ?5J([*0.2&T@_Z#W69H$+ ,>I:@_
M4NM]DR,Y)<-*ZJD[;HC-L^F<HANW(V NP'?6+J&\KO*62+@C%6.P+Z]S*70H
MXRFH*VV7@ZID@"4(H-#)$P=G@\*KDR94OEYU'TBM<LGX?8Z6QGE=G8VS!P1U
MXW!F /X1H=T@**I,T5.2(T[U!<!R(U?)6[8.)K"1B[<2&#A("%,I+\#9M=V4
M[I?1PEZS3B=-0TJ7GQ!>SARP8W2Y#,DP$ ,,6%/^,D%@CK6-$FBZ\";?FUM2
MC"4'MB2'8N0\]&Z5#H/<%%':!<_I+Q#")NT8$)A6VX^9DS-I(W8=RL/"^7#*
MB?>T<$(WYXC9)I1=,'9,P"7C(C&J,35=F7HJB_HC! )G?)"%-<U4G9'=B5:Q
MEH*ZS(Q10]89B?95XA6"-6D,:_=&.,=X143&#+ GWYD#&I4565PTXD":U-QI
MS100[F$9+&AL^!-U[+0,**QE1Z0T8)"W89'6;HDQ+!=0Q2R:[3".#,L&Q_7)
M45FEXO<8+B7OU=D?, IJ>M 487Y& -^?@G7&ZC7OU[RZUCW%+'2N!7@&Y$PW
M:A5L4UBOSHMQ82PRY')@; U-)Y0N0QEX)(T#RQYC+K?S[.=9F8P4&[T4V.(
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M   1              "  0    !N8FEX+3(P,C(P,3 V+FAT;5!+ 0(4 Q0
M   (  .!)E1WUQ5Z:P(  '0'   1              "  <\5  !N8FEX+3(P
M,C(P,3 V+GAS9%!+ 0(4 Q0    (  .!)E2R5Y.;60H  !A=   5
M      "  6D8  !N8FEX+3(P,C(P,3 V7VQA8BYX;6Q02P$"% ,4    "  #
M@294;,CYMZX&  #@,   %0              @ 'U(@  ;F)I>"TR,#(R,#$P
M-E]P<F4N>&UL4$L! A0#%     @  X$F5(R/RE0('0  'K4  !L
M     ( !UBD  &YB:7@M,C R,C Q,#=E>&AI8FET.3DQ+FAT;5!+!08
..!0 % $T!   71P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
